ESGO 2019 - 21st Biennial International Meeting of the European Society of Gynaecological Oncology
Nov 02 - Nov 05, 2019 | AthensGreece
LARVOL is not affiliated with 21st Biennial International Meeting of the European Society of Gynaecological Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 42 abstracts linked to Trials
SUCCOR study. An international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 (FIGO 2009,< 4 cm) cervical cancer operated in 2013-2014
SENTIX - Sentinel lymph node in patients with cervical cancer: time to voiding recovery after surgery (CEEGOG-CX01; ENGOT-CX2; NCT02494063)
Topical Imiquimod treatment of high-grade cervical intraepithelial neoplasia (TOPIC-3) study: a multicentre, non-randomized controlled study
Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial
Surgical staging prior to chemoradiation is beneficial for survival in patients with high stage cervical cancer
Bevacizumab combined with first-line carboplatin and paclitaxel for metastatic/recurrent/persistent cervical cancer: primary results from the global single-arm phase II CECILIA study
Patient-centred outcomes in the Phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age
SENTIX – sentinel lymph nodes in patients with cervical cancer: SLN detection and the false negative rate of SLN frozen section (CEEGOG-CX01; ENGOT-CX2; NCT02494063)
Adjuvant locoregional chemo-irradiation followed by sequential chemotherapy for high risk endometrial cancer, single centre real-world experience
European, non-interventional, phase IV NIMES-ROC trial of trabectedin plus pegylated liposomal doxorubicin in patients with platinum-sensitive recurrent ovarian cancer: an interim analysis
Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial
Prognostic relevance of the molecular classification in high-risk endometrial cancer: analysis of the PORTEC-3 trial
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer after chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 study
Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab
Effect of Progression-Free Interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the Phase 3 study ARIEL3